The purpose of this study is to investigate whether the study medication can help people with mild to moderate Alzheimer’s Disease improve their mental abilities such as understanding, reasoning, and judgment. The study medication will be given together with an FDA-approved Alzheimer’s medication: Aricept® (donepezil), Exelon® (rivastigmine) or Razadyne® (galantamine).
More about the study:
- The study drug (MK-7622) is administered in the form of one capsule a day in the morning.
- There will be 830 participants in this trial
If you are interested, please find the full study details and eligibility criteria listed here.
- be between 55 – 85 years old
- be diagnosed with mild to moderate Alzheimer’s Disease (12 – 24 MMSE)
- have a trial partner who is able to attend any study visits that require assessment
- be currently taking a stable daily dose of acetylcholinesterase inhibitor (AChEI) such as Aricept® (donepezil), Exelon® (rivastigmine patch oral), or Razadyne® (galantamine)
Participants must not:
- have a history of seizures or epilepsy within the last 5 years
- have a history of mental illness
- have been diagnosed or treated for cancer within the past 5 years (excluding basal cell, squamous cell skin cancer, in situ cervical cancer and localized prostate cancer)
If you’re not familiar with clinical trials, here are some FAQs:
What are clinical trials?
Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.
Why participate in a clinical trial?
You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.